Immune response of prostatic cancer patients to cytomegalovirus-infected and -transformed human cells.
The indirect immunofluorescent test was used to determine the prevalence of humoral immunity to cytomegalovirus (CMV)-induced antigens in prostatic cancer patients as compared to age-matched controls. Significantly more prostatic cancer patients demonstrated high CMV-antibody titers than did the benign prostatic hyperplasia and nonurogenital cancer groups; however, no significant difference in reactivity was found between paients with prostatic cancer and transitional cell carcinoma of the urinary bladder. When screened against CMV-transformed human cell lines, the reactivity of the sera followed the rate of expression of CMV-related antigens of cell lines used in these tests.
D000368:Aged; D000912:Antibodies, Neoplasm; D000914:Antibodies, Viral; D000951:Antigens, Neoplasm / Q000008:administration & dosage; D000956:Antigens, Viral / Q000008:administration & dosage; D002295:Carcinoma, Transitional Cell / Q000276:immunology; D002460:Cell Line; D002471:Cell Transformation, Neoplastic; D003587:Cytomegalovirus / Q000276:immunology*; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000276:immunology; D011470:Prostatic Hyperplasia / Q000276:immunology; D011471:Prostatic Neoplasms / Q000209:etiology / Q000276:immunology*; D001749:Urinary Bladder Neoplasms / Q000276:immunology
D000912:Antibodies, Neoplasm; D000914:Antibodies, Viral; D000951:Antigens, Neoplasm; D000956:Antigens, Viral